Complement C3 is a risk factor for the development of diabetes: A population-based cohort study

Diabetes

Volumn 54, Issue 2, 2005, Pages 570-575

  Engström, Gunnar ^a,b   Hedblad, Bo ^a   Eriksson, Karl Fredrik ^a   Janzon, Lars ^a   Lindgärde, Folke ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CERULOPLASMIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FIBRINOGEN; GLUCOSE; HAPTOGLOBIN; INSULIN; OROSOMUCOID; PLASMA PROTEIN;

ADULT; ARTICLE; BODY MASS; COMPLEMENT BLOOD LEVEL; DIABETES MELLITUS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

BLOOD GLUCOSE; BODY MASS INDEX; COMPLEMENT C3; COMPLEMENT C4; DIABETES MELLITUS; FOLLOW-UP STUDIES; HOMEOSTASIS; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK FACTORS; SMOKING; SWEDEN; TIME FACTORS;

EID: 12744279313     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.2.570     Document Type: Article

References (39)

1. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 18:1-8, 2004
2. Moshage H: Cytokines and the hepatic acute phase response. J Pathol 181:257-266, 1997
3. Gabrielsson BG, Johansson JM, Lönn M, Jernas M, Olbers T, Peltonen M, Larsson I, Lönn L, Sjöstrom L, Carlsson B, Carlsson LM: High expression of complement components in omental adipose tissue in obese men. Obes Res 11:699-708, 2003
4. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP: Effect of body weight and caloric restriction on serum complement proteins, including factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol 108:507-515, 1997
5. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, Descovich GC, Puddu P: Association of serum C3 levels with the risk of myocardial infarction. Am J Med 98:357-364, 1995
6. Peake PW, Kriketos AD, Campbell LV, Charlesworth JA: Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes Relat Metab Disord Apr. 27, 2004 [Epub ahead of print]
7. Figueredo A, Ibarra JL, Bagazgoitia J, Rodriguez A, Molino AM, Fernandez-Cruz A, Patino R: Plasma C3d levels and ischemic heart disease in type II diabetes. Diabetes Care 16:445-449, 1993
8. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P, Puddu P: Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 21:1081-1090, 2000
9. Weyer C, Tataranni PA, Pratley RE: Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 23:779-785, 2000
10. Cianflone K, Xia Z, Chen LY: Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 1609:127-143, 2003
11. Maslowska M, Sniderman AD, Germinario R, Cianflone K: ASP stimulates glucose transport in cultured human adipocytes. Int J Obes Relat Metab Disord 21:261-266, 1997
12. Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nilsell K, Sniderman A, Arner P: Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274:18243-18251, 1999
13. Xia Z, Sniderman AD, Cianflone K: Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J Biol Chem 277:45874-45879, 2002
14. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 163:93-99, 2003
15. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N, West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600, 2002
16. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389, 2001
17. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016-2021, 2002
18. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649-1652, 1999
19. Ford ES: Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol 155:57-64, 2002
20. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
21. Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
22. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis Study: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
23. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F: Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 105:2632-2637, 2002
24. Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgärde F: Inflammations-sensitive plasma proteins are associated with future weight gain. Diabetes 52:2097-2101, 2003
25. Engström G, Lind P, Hedblad B, Berglund G, Stavenow L, Janzon L, Lindgärde F: Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol 22:2054-2058, 2002
26. Berglund G, Eriksson KF, Israelsson B, Kjellström T, Lindgärde F, Mattiasson I, Nilsson JA, Stavenow L: Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmö Preventive Project. J Intern Med 239:489-497, 1996
27. Thorell JI, Larson SM: Radioimmunoassay and Related Techniques. St. Louis, MO, CV Mosby, 1978, p. 205-211
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
29. Laurell CB: Electroimmunoassay. Scand J Clin Lab Invest Suppl 124:21-37, 1972
30. Hotamisligil GS: The role of TNF-a and TNF receptors in obesity and insulin resistance. J Intern Med 245:621-625, 1999
31. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H: Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 18:1199-1202, 1998
32. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978, 1999
33. Arner P: The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14:137-145, 2003
34. Koistinen HA, Vidal H, Karonen SL, Dusserre E, Vallier P, Koivisto VA, Ebeling P: Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 21:1034-1039, 2001
35. Murray I, Sniderman AD, Havel PJ, Cianflone K: Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J Biol Chem 274:36219-36225, 1999
36. Matsuda M, Defronzo RA, Glass L, Consoli A, Giordano M, Bressler P, Delprato S: Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51:1111-1119, 2002
37. Blumberg D, Hochwald S, Brennan MF, Burt M: Interleukin-6 stimulates gluconeogenesis in primary cultures of rat hepatocytes. Metabolism 44:145-146, 1995
38. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067, 2004
39. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157, 1999